Skip to main content
S

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,652 across all filing types
Latest filing 2026-05-11 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement of the 2025 Annual General Meeting resolutions, detailing proposals approved, voting methods, attendance, and vote counts. It reports the official voting results from a shareholder meeting rather than the presentation materials or the full annual report. This matches the Declaration of Voting Results & Voting Rights Announcements category.
2026-05-11 Chinese
关于JK07（SAL007）治疗慢性心力衰竭的RENEU-HF临床研究进展的公告
Regulatory Filings Classification · 85% confidence The document is a corporate announcement detailing the progress and interim data of a Phase II clinical trial for a drug candidate. It contains no financial statements, earnings metrics, AGM materials, voting results, management changes, or capital transactions. It is purely a regulatory-style announcement of clinical development progress. There is no indication of an attached or full detailed report; rather it’s an information disclosure notice. This best fits the General Regulatory Filings category (RNS) as a miscellaneous regulatory announcement that does not fit other specific categories.
2026-05-10 Chinese
关于增加套期保值型金融衍生品业务交易额度的公告
Regulatory Filings Classification · 75% confidence The document is a public announcement by Shenzhen Xinlitai Pharma Co. Ltd regarding the board’s approval and planned submission to the shareholders’ meeting for increasing the trading limit of hedging financial derivatives. It is not a full financial report or earnings release, nor is it an actual financing of equity or debt. It is a specific regulatory disclosure under exchange rules for miscellaneous corporate actions that do not fit other precise categories. Therefore, it falls under the general Regulatory Filings category (RNS).
2026-04-20 Chinese
关于召开2025年年度股东会的通知
AGM Information Classification · 91% confidence The document is a detailed notice of the 2025 Annual General Meeting (AGM) of Shenzhen Salubris Pharmaceuticals Co., providing meeting time, venue, agenda items, registration procedures, voting methods, attachments, and proxy forms. It is not the minutes or results of the meeting, nor is it an earnings announcement or report publication announcement. This clearly matches the definition of AGM Information (AGM-R).
2026-04-20 Chinese
关于2025年度利润分配预案的公告
Notice of Dividend Amount Classification · 95% confidence The document is a formal announcement by Shenzhen Salubris Pharmaceuticals of its 2025 profit distribution plan, specifying the cash dividend per 10 shares, total dividend amount, conditions, and related approvals. This fits the definition of a Notice of Dividend Amount (DIV).
2026-04-20 Chinese
深圳信立泰药业股份有限公司募集资金存放、管理与实际使用情况审核报告
Audit Report / Information Classification · 85% confidence The document is a specialized audit/review report (“募集资金存放、管理与实际使用情况审核报告”) issued by the external auditor (WUYIGE Certified Public Accountants LLP) on the company’s special report of raised‐funds deposit, management, and use, followed by the company’s own detailed “专项报告.” This is a standalone audit engagement report (not a full annual report or earnings release), matching the definition of a standalone audit report/information. Therefore, the appropriate classification is AR (Audit Report / Information).
2026-04-20 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.